Core Viewpoint - Holley Inc. (NYSE: HLLY) is facing a federal securities fraud class action lawsuit, with allegations that the company misled investors regarding its financial health and relationships with resellers and distributors [2][3]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Holley Inc. made false or misleading statements about its direct-to-consumer (DTC) channel, which negatively impacted its relationships with resellers and distributors, crucial for the majority of its revenue [2]. - It is alleged that Holley's focus on the DTC channel led to significant damage to its relationships with resellers and distributors, resulting in decreased purchases and increased returns of products [2]. - The company reportedly used discounting strategies to grow its DTC channel, undermining its historical pricing discipline with resellers and distributors [2]. - The lawsuit asserts that Holley's DTC growth could not compensate for the negative financial impacts stemming from strained relationships with resellers and distributors [2]. - Holley is accused of failing to integrate and capture synergies from its acquisitions, leading to operational inefficiencies and inventory management issues [2]. - The complaint highlights that Holley benefited from temporary COVID-related stimulus funds, misleading investors into believing that the resulting growth was sustainable [2]. Group 2: Legal Proceedings - The court has determined that the complaint has sufficiently pleaded allegations of falsity and scienter, meeting the necessary legal standards to survive a motion to dismiss [3]. - The court found that the complaint adequately listed misleading statements made by company leadership and provided reasons for their falsity [3]. Group 3: Shareholder Actions - Current shareholders of Holley who have held shares since on or shortly after July 21, 2021, can seek corporate reforms and the return of funds to the company at no cost [4].

Core Viewpoint - A securities class action lawsuit has been filed against Sprouts Farmers Market, Inc. for allegedly making false and misleading statements regarding its financial health and growth prospects during the specified Class Period from June 4, 2025, to October 29, 2025 [1][2]. Allegations Against Defendants - The lawsuit claims that Sprouts' reports of growth and stability were overly optimistic and did not reflect the reality of macroeconomic conditions [2]. - It is alleged that Sprouts' consumer base was not as resilient as claimed, leading to reduced spending [2]. - The anticipated benefits from macroeconomic pressures did not materialize, resulting in Sprouts failing to meet its growth projections [2]. - Consequently, the positive statements made by the defendants regarding the company's business and prospects were materially false and misleading [2]. Lead Plaintiff Process - Investors in Sprouts have until January 26, 2026, to seek appointment as a lead plaintiff representative for the class [3]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and represents both individual and institutional investors [4]. - The firm has a strong track record in securities litigation and has received numerous accolades for its work [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates and the quality of its supply chain [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% decline year-over-year, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of Q3 2025 financial results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The decline was attributed to customers requiring more customization for IP components, which negatively impacted the economics of the Design IP business [5][6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride acknowledged that poor customer experience led to an estimated 10,000-15,000 fewer enrollments, causing its stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - The complaint alleges that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming sustainable customer demand when, in fact, sales were driven by inventory loading by channel partners [5]. - The company stated on May 20, 2025, that it was experiencing "normal stock levels" and expected performance, which was later contradicted by actual sales data [5]. Group 4: Stock Performance - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer announced a reduction in its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6] - The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, alongside slower adoption rates for two of its EP devices [6] - Following this announcement, Integer's stock price plummeted by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Freeport-McMoRan securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by January 12, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing their capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Freeport-McMoRan made false and misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which posed a heightened risk to workers [5]. - It is claimed that the lack of proper safety measures led to undisclosed risks of regulatory, litigation, and reputational damage, affecting the company's business statements [5]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading information provided by the defendants [5].

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly making false and misleading statements regarding its business operations and prospects during the class period from June 6, 2024, to November 10, 2025 [1][2]. Summary by Sections Allegations Against Defendants - The complaint claims that Bitdeer misrepresented its SEAL04 chip design progress, leading to production delays [2] - Bitdeer adopted a "dual-track approach" to create two independent designs to compensate for lost progress, while still assuring the public that production timelines were on track [2] - As a result, the statements made by the defendants regarding the company's business and operations were materially false and misleading [2] Lead Plaintiff Process - Investors in Bitdeer can seek to be appointed as lead plaintiff by February 2, 2026, or choose to remain absent from the class [3] - The lead plaintiff will represent all class members and select counsel to direct the litigation [3] - Participation as a lead plaintiff does not affect the ability to share in any recovery [3] About Kessler Topaz Meltzer & Check, LLP - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection [4] - The firm has a strong track record in securities litigation and has received numerous accolades for its work [4] - KTMC operates globally with offices in Pennsylvania and California [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026, for a class action lawsuit related to alleged misrepresentations about the company's sleep apnea device, Inspire V [1][5]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit a form online or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by January 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [4]. Group 3: Allegations Against Inspire Medical - The lawsuit claims that Inspire Medical misrepresented key facts about the market demand for its Inspire V device and failed to disclose whether necessary steps for its launch were taken, leading to misleading statements that inflated investor confidence [5]. - When the true details about the product and its market performance became known, investors allegedly suffered damages [5].